Disclosure: This is an affiliate site. We may earn compensation from partners. Full disclosure | Medical disclaimer
FDA-approved April 1, 2026 — a once-daily tablet with no food or water restrictions, from $149 a month.
For years the practical objection to GLP-1 therapy was the injection. Foundayo removes it. Approved by the FDA on April 1, 2026, orforglipron is a once-daily oral GLP-1 for chronic weight management, and the only GLP-1 pill for weight loss that can be taken at any time of day without food or water restrictions.
That last detail matters more than it sounds. Oral semaglutide — the Wegovy tablet — requires taking it on an empty stomach with a small sip of water and waiting before eating or drinking anything else. Orforglipron is a non-peptide small molecule rather than a peptide, so it does not carry those constraints.
It was also the first new molecular entity approved under the FDA's National Priority Voucher program. And because there is no injection, there is no cold chain: no refrigerated shipping, no cooler bags, no worrying whether a delivery sat on a doorstep in July.
Foundayo is orforglipron, an FDA-approved once-daily oral GLP-1 from Eli Lilly for chronic weight management. Dosing starts at 0.8 mg and escalates roughly every 30 days. Self-pay pricing starts at $149 a month through LillyDirect, GoodRx and Amazon One Medical. From July 1, 2026 it is covered at $50 a month for eligible Medicare beneficiaries under the GLP-1 Bridge program.
Lilly's prescribing information sets out a stepwise escalation designed to reduce gastrointestinal side effects. Each step is held for at least 30 days before increasing.
| Step | Dose | Duration | Notes |
|---|---|---|---|
| Starting dose | 0.8 mg once daily | At least 30 days | Taken any time of day, with or without food or water |
| Step 2 | 2.5 mg once daily | At least 30 days | First escalation after the starting period |
| Subsequent steps | Escalating strengths | ~30 days each | Escalation continues under your prescriber's direction |
| Higher strengths | 14.5 mg and 17.2 mg | Maintenance | The highest available strengths |
This is a summary, not a prescribing instruction. Your dose and escalation schedule are set by your prescriber based on tolerance and response. Never adjust a GLP-1 dose on your own.
Weight loss increased with dose in the clinical program. At the 17.2 mg dose — the highest strength — Foundayo produced the greatest average weight loss at 11.1%, or roughly 25.2 pounds. Reported figures across the phase 3 program cluster in the 11% to 12.4% range.
That is meaningful, but it places Foundayo below the injectable options rather than alongside them. In the SURMOUNT-5 head-to-head trial, tirzepatide produced an average weight loss of 20.2% against semaglutide's 13.7%. Orforglipron trails both.
So the trade-off is clear. If maximum weight loss is your priority, injectable tirzepatide remains the most effective option available. If avoiding injections, refrigeration and cold-chain shipping matters more to you — or if you have tried an injectable and could not tolerate it — Foundayo offers real efficacy in a form many people find far easier to sustain.
Side effects are predominantly gastrointestinal and are most pronounced during dose escalation, which is precisely why the titration schedule is gradual.
| Side effect | Reported frequency | Notes |
|---|---|---|
| Nausea | 26-35% | The most common; usually worst after a dose increase |
| Constipation | 20-27% | Hydration and fibre help; discuss persistent cases with your prescriber |
| Diarrhea | 21-25% | Commonly reported alongside other GI effects |
| Vomiting | Common | Listed among the most common side effects by Lilly |
| Indigestion (dyspepsia) | Common | Mostly mild and transient |
| Abdominal pain | Common | Severe or persistent pain warrants urgent medical attention |
| Headache | Common | Listed among the most common side effects |
Gastrointestinal events with orforglipron were mostly mild to moderate and most frequent during titration. This list is not exhaustive — read the full prescribing information and speak to your prescriber about warnings, contraindications and serious risks.
Foundayo has launched with unusually competitive self-pay pricing — the lowest published entry price of any branded GLP-1 for weight loss.
| Where | Starting price | Higher doses | Notes |
|---|---|---|---|
| LillyDirect | $149/mo | $199 for 2.5 mg, $299 higher; $349 for 14.5 mg and 17.2 mg | Manufacturer-direct; $29 independent telehealth visits available |
| GoodRx for Weight Loss | From $149/mo | Varies by dose | $39/mo introductory care subscription; standard rate $119/mo |
| Amazon One Medical | $149-$299/mo cash-pay | Dose-tiered | $29 message consult or $49 video visit; as low as $25/mo with insurance |
| Walgreens Virtual Healthcare | From $149/mo | Subsequent doses $399-$449 | $49 per visit, no subscription; in-store pickup |
| Medicare GLP-1 Bridge | $50/mo | Same | Eligible beneficiaries, July 1, 2026 through December 31, 2027 |
These are the two FDA-approved oral GLP-1 options for weight loss, and they are not the same kind of drug. Wegovy tablets are oral semaglutide — a peptide, delivered orally with absorption enhancers. Foundayo is orforglipron, a non-peptide small molecule designed from the outset for oral administration.
The practical difference is how you take them. Oral semaglutide requires an empty stomach, a small sip of water, and a waiting period before eating or drinking. Foundayo has no such restrictions and can be taken at any time of day. For anyone whose morning is not tightly controlled, that is a meaningful advantage.
On efficacy, reporting to date suggests oral semaglutide shows slightly higher average weight loss than orforglipron. On price, both start at $149 a month self-pay. If you want the simplest possible daily routine, Foundayo wins; if you want the marginally stronger oral result, the Wegovy pill has the edge.
Yes. The FDA approved Foundayo (orforglipron) on April 1, 2026 for chronic weight management in adults, used with a reduced-calorie diet and increased physical activity. It was the first new molecular entity approved under the FDA's National Priority Voucher program.
Self-pay pricing starts at $149 a month for the 0.8 mg starting dose through LillyDirect. U.S. News reports $199 for 2.5 mg and $299 for higher doses, with regular prices of $349 for the 14.5 mg and 17.2 mg strengths. GoodRx and Amazon One Medical also offer it from $149. Eligible Medicare beneficiaries can get it for $50 a month through the GLP-1 Bridge program from July 1, 2026.
Dosing begins at 0.8 mg once daily. After at least 30 days, the dose increases to 2.5 mg, with further escalation roughly every 30 days under your prescriber's direction. The gradual schedule is designed to reduce gastrointestinal side effects.
Weight loss increased with dose in the clinical program. The 17.2 mg dose produced the greatest average weight loss at 11.1%, or about 25.2 pounds. Figures across the phase 3 program cluster in the 11% to 12.4% range. For context, tirzepatide averaged 20.2% and injectable semaglutide 13.7% in the SURMOUNT-5 head-to-head trial.
The most common are gastrointestinal: nausea (26-35%), constipation (20-27%), diarrhea (21-25%), vomiting, indigestion, abdominal pain and headache. They are mostly mild to moderate and most frequent during dose escalation. This is not a complete list — read the full prescribing information and discuss warnings and contraindications with your prescriber.
No. Zepbound (tirzepatide) produced an average weight loss of 20.2% in the SURMOUNT-5 head-to-head trial, against roughly 11% for orforglipron in its own program. Foundayo's advantage is not potency — it is that it is a pill with no injections, no refrigeration and no food or water restrictions.
No. Foundayo is an oral tablet, so it does not require the refrigerated storage at 2-8°C that injectable GLP-1s need. That also means no cold-chain shipping concerns and much easier travel.
Yes. Foundayo is the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. This distinguishes it from oral semaglutide, which must be taken on an empty stomach with a small sip of water and a waiting period before eating.
The other FDA-approved oral GLP-1
Manufacturer-direct at $149/mo
How the injectables compare
Foundayo at $50/mo from July 2026
Where to get FDA-approved GLP-1s
Managing GI effects during titration
Claims on this page trace to the following sources, checked on August 30, 2026.
Explore more expert guides and reviews to help you on your weight loss journey
Complete guide explaining the difference between semaglutide, Ozempic, Wegovy, and compounded semaglutide.
Complete guide to Jardiance weight loss: how much to expect, mechanism, and comparison to GLP-1 medications.
The SURMOUNT-5 head-to-head trial: 20.2% vs 13.7% average weight loss, plus side effects and cost.
What actually differs, what the FDA changed in 2026, and how the price gap closed.
The higher-dose semaglutide approved March 19, 2026, delivering 20.7% mean weight loss.
Retatrutide at up to 30.3%, CagriSema at 22.7%, and realistic timelines for the GLP-1 pipeline.
This article summarizes publicly available information about Foundayo (orforglipron) and is for informational purposes only. It is not medical advice, a diagnosis, a treatment recommendation, or a substitute for the FDA-approved prescribing information. Foundayo is a prescription medicine with serious potential risks and is not appropriate for everyone. Dosing decisions must be made by a licensed prescriber. Always read the full prescribing information and consult a qualified healthcare provider. This page contains affiliate links, and we may earn compensation if you use them.
Date reviewed: August 30, 2026